BioCentury
ARTICLE | Top Story

Active Biotech swaps partners

August 8, 2000 7:00 AM UTC

Active Biotech (SSE:ACTI) terminated its collaboration with SmithKline Beecham (SBH; LSE:SB) to develop a diarrhea vaccine and took up with Aventis Pasteur, the vaccines division of Aventis Pharma (AVE), in the field of diarrhea diseases.

ACTI took back the global rights to its ETEC vaccine, to prevent travelers' diarrhea, from SBH. ETEC is marketed as Dukoral in Sweden and Norway and is in ongoing Phase III trials in Mexico and Guatemala; the trials will continue as planned. AVE will apply for registration for Dukoral in various international markets. Additionally, ACTI took back the international marketing rights to its drinkable cholera vaccine, SBL Cholera Vaccine. AVE will assume responsibility for marketing, sales and distribution of SBL Cholera Vaccine for all countries worldwide outside the U.S. and Europe. Under the deal with AVE, ACTI will manufacture the SBL Cholera Vaccine and Dukoral. ...